Because the pathological features such as impaired insulin signal seem to be shared by T2DM patients who use pioglitazone alone and patients with AD, we speculated that mechanisms analogous to those that account for peripheral insulin resistance in T2DM may underlie impaired brain insulin signalling in pioglitazone-induced development of AD. This evidence concerns the gene INS and type 2 diabetes mellitus.